Get the Stockscreener App
0.7608
3.99%
0.0292
After Hours:
.75
-0.0108
-1.42%
Filana Therapeutics Inc stock is traded at $0.7608, with a volume of 247.97K.
It is up +3.99% in the last 24 hours and up +9.23% over the past month.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
See More
Previous Close:
$0.7316
Open:
$0.713
24h Volume:
247.97K
Relative Volume:
0.39
Market Cap:
$36.75M
Revenue:
Net Income/Loss:
$-77.90M
P/E Ratio:
-0.4718
EPS:
-1.6127
Net Cash Flow:
$-30.38M
1W Performance:
-6.49%
1M Performance:
+9.23%
6M Performance:
-52.75%
1Y Performance:
+0.00%
1-Day Range:
$0.702
$0.77
1-Week Range:
$0.702
$0.8419
52-Week Range:
$0.6701
$2.2665
Filana Therapeutics Inc Stock (FLNA) Company Profile
Name
Filana Therapeutics Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN
Compare FLNA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLNA
Filana Therapeutics Inc
|
0.7608 | 36.75M | 0 | -77.90M | -30.38M | -1.6127 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Filana Therapeutics Inc Stock (FLNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Filana Therapeutics Inc Stock (FLNA) Latest News
Diluted net income available to common stockholders of Filana Therapeutics, Inc. – HAN:PX91 - TradingView
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit - GlobeNewswire Inc.
Form 4 Filana Therapeutics, Inc For: 1 October By Investing.com - Investing.com Canada
Filana Therapeutics CEO Barry Richard buys $278k in company stock - Investing.com
Filana Therapeutics CEO Barry Richard buys $278k in company stock - Investing.com Canada
Form 4 Filana Therapeutics, Inc For: 1 October By Investing.com - Investing.com UK
Form 4 Filana Therapeutics, Inc For: 1 October By Investing.com - Investing.com India
Filana Therapeutics CEO Richard Barry Acquires 93,091 Shares at $0.84 Each - Kalkine Media
Scienture Holdings, Inc. (SCNX) Stock Price & News - Syfe
Kairos Pharma, Ltd. (KAPA) Stock Price & News - Syfe
Unusual volume stocks in Wednesday's session - ChartMill
Gapping stocks in Wednesday's session - ChartMill
FDA clears Filana (NASDAQ: FLNA) to test simufilam in hard-to-treat seizures - Stock Titan
A rare epilepsy trial can now move ahead after FDA lifts its hold on simufilam. - Stock Titan
Filana Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - tradingview.com
Filana Therapeutics Receives Nasdaq Minimum Bid Price Notice - TipRanks
Filana Therapeutics, Inc. Stock Price Today | FLNA Live Chart & News - Traders Union
Lantern Pharma Inc. (LTRN) Stock Price & News - Syfe
Valion Bio, Inc. (VBIO) Stock Price & News - Syfe
Filana (FLNA) Latest Quarter: EPS Clears the Reported Estimate in the Latest Reading; Post-Report: Shares Close 3.23% Lower in Latest TradingEarnings Miss Streak - vinanet.vn
Filana (FLNA) Latest Quarter: EPS Clears the Reported Estimate in the Latest Reading; Post-Report: Shares Close 3.23% Lower in Latest TradingCEO Earnings Statement - vinanet.vn
Filana (FLNA) Earnings Snapshot: The EPS Result Is Above Expectation in Latest Trading; After Results: The Market Price Declines 3.72% for the Current SessionMargin Compression Risk - vinanet.vn
Filana Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | PX91 | US14817C1071 - marketscreener.com
Cassava Sciences Securities Litigation Ruling: Court Denies Ugarte Dismissal Motions Without Prejudice While Awaiting Fifth Circuit Ruling - TipRanks
Law firm investigates Filana Therapeutics officers for possible shareholder rights breaches - Pluang
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Morningstar
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
FLNA Q3 2025 Earnings: Narrower Loss Beats Estimates by 20.12% as Shares Dip 2.58%Earnings Manipulation Risk - vinanet.vn
FLNA Q3 2025 Earnings: Narrower Loss Beats Estimates; Stock Gains 0.2%Peak Earnings Alert - vinanet.vn
Filana Therapeutics (FLNA) Climbs 3.75% as Micro-Cap Biotech Approaches Key Resistance at $1.04Volatility Smile - dars.gov.et
Filana Therapeutics (FLNA) Climbs 3.75% as Micro-Cap Biotech Approaches Key Resistance at $1.04Insider Sentiment - careplusvn.com
Filana Therapeutics (FLNA) Climbs 3.75% as Micro-Cap Biotech Approaches Key Resistance at $1.04Revenue Weighted - dars.gov.et
Filana Therapeutics, Inc. (NASDAQ: FLNA) Share Price, FLNA Stock News, FLNA Share Price & Updates - kalkine.ca
Filana Therapeutics, Inc. (NASDAQ: FLNA) Share Price, FLNA Stock News, FLNA Share Price & Updates - Kalkine
Filana Therapeutics (FLNA) Slides 3.3% to $1.00 as Small-Cap Biotech Approaches Key SupportEarnings Miss Risk - dars.gov.et
Weekly Recap: FDA clinical hold on TSC trial and Q2 2026 cash $82.7M - TradingView
FLNA Q3 2025 Earnings: Narrower-than-Expected Loss Lifts Shares 5.21%Negative Surprise Momentum - vinanet.vn
Maxim Group Maintains Filana Therapeutics(FLNA.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update - GlobeNewswire
Filana Therapeutics Q2 EPS beats estimate, loss narrows 81% - scanx.trade
Filana Therapeutics Faces Pressure as Shares Slide 4.43%Support at $0.85 in FocusIV Spike - vinanet.vn
Filana Therapeutics, Inc. Revenue Breakdown – NASDAQ:FLNA - TradingView
Filana Therapeutics (FLNA) AGM 2026 Summary - Quartr
Filana Therapeutics (FLNA) Q4 2025 earnings summary - Quartr
Filana Therapeutics (FLNA) Slides 5% as Bearish Momentum Builds; Key Support at $1.04 in FocusATR Stop - dars.gov.et
MSN Money - MSN
MSN Money - MSN
MSN Money - MSN
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Despite Stock SlideEPS Surprise History - dars.gov.et
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Despite Stock SlideConsensus Forecast Report - DonanımHaber
Filana Therapeutics Inc Stock (FLNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Filana Therapeutics Inc Stock (FLNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barry Richard | President & CEO |
Sep 30 '26 |
Buy |
0.92 |
100,000 |
92,000 |
1,337,964 |
| Barry Richard | President & CEO |
Sep 28 '26 |
Buy |
0.84 |
93,091 |
78,196 |
1,031,151 |
| Anderson Robert Eugene Jr | Director |
Nov 24 '25 |
Buy |
2.90 |
8,600 |
24,940 |
8,600 |
| Barry Richard | President & CEO |
Nov 20 '25 |
Buy |
2.76 |
150,000 |
414,000 |
938,060 |
| Barry Richard | President & CEO |
Nov 19 '25 |
Buy |
2.75 |
73,385 |
201,809 |
788,060 |
| Cook Robert Christopher | Chief Operating & Legal Office |
Sep 30 '25 |
Buy |
2.91 |
13,725 |
39,940 |
13,725 |
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):